Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
SCOTTSDALE, AZ—Lisa K. Miller, Executive Vice President of Practice Operations at LifeStance Health Group, Inc. (NASDAQ:LFST), recently sold shares of the company’s common stock. The company, currently valued at $2.6 billion, has shown strong revenue growth of 18.5% over the last twelve months, though InvestingPro analysis indicates the stock is trading slightly below its Fair Value. According to a filing with the Securities and Exchange Commission, Miller sold 18,845 shares on March 17, 2025, at a weighted average price of $6.90 per share. The transactions, which occurred at prices ranging from $6.89 to $6.91, amounted to a total value of approximately $130,030. The stock, which has demonstrated relatively low price volatility, currently trades near $6.73, with analysts setting price targets between $8 and $11.
Following the sale, Miller holds 339,810 shares of LifeStance Health Group. The sale was conducted directly by Miller, as indicated in the filing. While the company operates with moderate debt levels, InvestingPro data reveals a strong financial health score and analysts expect profitability improvements this year. Discover more insights and 8 additional ProTips for LFST with an InvestingPro subscription.
In other recent news, LifeStance Health Group Inc. reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of -$0.01, compared to the forecasted -$0.0383. The company’s revenue for the quarter was $325.5 million, exceeding the anticipated $313.91 million. LifeStance achieved a significant milestone by reporting its first-ever double-digit EBITDA margin, reflecting improved operational efficiency. The company also demonstrated solid performance with a 16% year-over-year revenue growth and a 62% increase in adjusted EBITDA, reaching $33 million for the quarter. For the full year 2024, LifeStance reported revenue of $1.251 billion, marking a 19% growth, and adjusted EBITDA of $120 million, a 103% increase from the previous year. Looking ahead, LifeStance projects 2025 revenue between $1.400 billion and $1.440 billion, with adjusted EBITDA expected to range from $130 million to $150 million. Additionally, the company plans to open 25-30 new centers in 2025 and anticipates achieving positive net income by 2026. Analyst firms have noted LifeStance’s strong financial performance and future growth potential, particularly in light of the company’s leadership transition and strategic plans.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.